Skip to main content

SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials

Acta Diabetologica volume 55, pages 503–514 (2018)Cite this article

Abstract

Aims

There is concern about the infection-related safety profile of sodium–glucose co-transporter 2 (SGLT-2) inhibitors. We aimed to determine the effect of SGLT-2 inhibitors on genitourinary and other infections via systematic review and meta-analysis of randomized controlled trials (RCTs).

Methods

We conducted a systematic search of Medline, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov to identify double-blinded RCTs enrolling ≥ 50 patients with type 2 diabetes which compared an SGLT-2 inhibitor to placebo or active comparator. Two independent reviewers extracted data and appraised study quality. Data were pooled using random-effects models.

Results

Eighty-six RCTs enrolling 50,880 patients were included. SGLT-2 inhibitors increased the risk of genital infections compared to placebo (relative risk [RR] 3.37, 95% CI 2.89–3.93, I2 0%) and active comparator (RR 3.89, 95% CI 3.14–4.82, I2 0.3%). The risk of urinary tract infection (UTI) was not increased with SGLT-2 inhibitors compared to placebo (RR 1.03, 95% CI 0.96–1.11, I2 0%) or active comparator (RR 1.08, 95% CI 0.93–1.25, I2 22%). In drug-specific analyses, only dapagliflozin 10 mg daily was associated with a significantly increased risk of UTI compared to placebo (RR 1.33, 95% CI 1.10–1.61, I2 0%). SGLT-2 inhibitors were associated with a reduced risk of gastroenteritis (RR 0.38, 95% CI 0.20–0.72, I2 0%) but did not affect the risk of respiratory tract infections.

Conclusions/interpretation

SGLT-2 inhibitors are associated with an increased risk of genital tract infections. Although there is no association overall between SGLT-2 inhibitors and UTI, higher doses of dapagliflozin are associated with an increased risk.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Monami M, Nardini C, Mannucci E (2014) Efficacy and safety of sodium glucose co-transport 2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16(5):457–466

    CAS  Article  PubMed  Google Scholar 

  2. Clar C, Gill J, Court R et al (2012) Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2(5):e001007

    Article  PubMed  PubMed Central  Google Scholar 

  3. Musso G, Gambino R, Cassader M et al (2012) A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44(4):375–393

    CAS  Article  PubMed  Google Scholar 

  4. Vasilakou D, Karagiannis T, Athanasiadou E et al (2013) Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159(4):262–274

    Article  PubMed  Google Scholar 

  5. Berhan A, Barker A (2013) Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord 13:58

    Article  PubMed  PubMed Central  Google Scholar 

  6. Liu X, Zhang N, Chen R et al (2015) Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J Diabetes Complicat 29(8):1295–1303

    Article  PubMed  Google Scholar 

  7. Johnsson K, Ptaszynska A, Schmitz B et al (2013) Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complicat 27(5):479–484

    Article  PubMed  Google Scholar 

  8. Food and Drug Administration (2015) FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm. Accessed 12 Jan 2016

  9. Food and Drug Administration (2016) FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm. Accessed 6 Aug 2016

  10. Yu S, Fu A, Qiu Y et al (2014) Disease burden of urinary tract infections among type 2 diabetes mellitus patients in the U.S. J Diabetes Complicat 28(5):621–626

    Article  PubMed  Google Scholar 

  11. Mnif M, Kamoun N, Kacem F et al (2013) Complicated urinary tract infections associated with diabetes mellitus: pathogenesis, diagnosis and management. Indian J Endocrinol Metab 17(3):442–445

    Article  PubMed  PubMed Central  Google Scholar 

  12. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006–1012

    Article  PubMed  Google Scholar 

  13. Health Information Research Unit (2004) Hedges. http://hiru.mcmaster.ca/hiru/HIRU_Hedges_home.aspx. Accessed 15 Mar 2015

  14. Higgins J, Green S (2008) Cochrane handbook for systematic reviews of interventions, version 5.0.0. The Cochrane collaboration. www.cochrane-handbook.org. Accessed 18 Aug 2016

  15. Lundh A, Sismondo S, Lexchin J et al (2012) Industry sponsorship and research outcome. Cochrane Database Syst Rev 12:MR000033

    PubMed  Google Scholar 

  16. Tahara A, Takasu T, Yokono M et al (2016) Characterization and comparison of sodium–glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci 130(3):159–169

    CAS  Article  PubMed  Google Scholar 

  17. Geerlings S, Fonseca V, Castro-Diaz D et al (2014) Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 10(3):373–381

    Article  Google Scholar 

  18. Rosenstock J, Ferrannini E (2015) Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38(9):1638–1642

    CAS  Article  PubMed  Google Scholar 

  19. Food and Drug Administration (2016) FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm531517.htm. Accessed 17 Jun 2017

  20. Zinman B, Wanner C, Lachin J et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128

    CAS  Article  PubMed  Google Scholar 

  21. Monami M, Dicembrini I, Mannucci E (2017) Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetol 54(1):19–36

    CAS  Article  PubMed  Google Scholar 

  22. Zaccardi F, Webb D, Htike Z et al (2016) Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 18(8):783–794

    CAS  Article  PubMed  Google Scholar 

  23. Wu J, Foote C, Blomster J et al (2016) Effects of sodium–glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 4(5):411–419

    CAS  Article  PubMed  Google Scholar 

  24. Shyangdan D, Uthman O, Waugh N (2016) SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open 6(2):e009417

    Article  PubMed  PubMed Central  Google Scholar 

  25. Li D, Wang T, Shen S et al (2017) Urinary tract and genital infections in patients with type 2 diabetes treated with sodium–glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 19(3):348–355

    CAS  Article  PubMed  Google Scholar 

  26. Saad M, Mahmoud A, Elgendy I et al (2017) Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: a meta-analysis of placebo-controlled randomized trials. Int J Cardiol 228:352–358

    Article  PubMed  Google Scholar 

  27. Storgaard H, Gluud L, Bennett C et al (2016) Benefits and harms of sodium–glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE 11(11):e0166125

    Article  PubMed  PubMed Central  Google Scholar 

  28. Tang H, Fang Z, Wang T et al (2016) Meta-analysis of effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus. Am J Cardiol 118(11):1774–1780

    CAS  Article  PubMed  Google Scholar 

  29. Sutton A, Cooper N, Lambert P et al (2002) Meta-analysis of rare and adverse event data. Expert Rev Pharmacoecon Outcomes Res 2(4):367–379

    Article  PubMed  Google Scholar 

  30. Walker E, Hernandez A, Kattan M (2008) Meta-analysis: its strengths and limitations. Cleve Clin J Med 75(6):431–439

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We wish to thank Mrs. Angella Lambrou, Liaison Librarian at the Life Sciences Library of McGill University, for her assistance in developing the database search strategies.

Funding

Drs. Filion and Azoulay are supported by Fonds de Recherche du Québec—Santé (FRQS) Junior II awards.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Toronto, Toronto, ON, Canada

    Robert Puckrin

  2. Deparment of Medicine, McGill University, Montreal, QC, Canada

    Marie-Philippe Saltiel & Kristian B. Filion

  3. Centre for Clinical Epidemiology, Lady Davis Institute, 3755 Cote Ste-Catherine Road, Suite H416.1, Montreal, QC, H3T 1E2, Canada

    Pauline Reynier, Laurent Azoulay & Kristian B. Filion

  4. Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada

    Laurent Azoulay

  5. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada

    Laurent Azoulay & Kristian B. Filion

  6. Division of Endocrinology, Jewish General Hospital, Montreal, QC, Canada

    Oriana H. Y. Yu

Authors
  1. Robert Puckrin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie-Philippe Saltiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pauline Reynier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laurent Azoulay
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Oriana H. Y. Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kristian B. Filion
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RP and MS conducted the literature search, performed data extraction, and assessed study quality. PR conducted the statistical analyses. RP wrote the manuscript. All authors interpreted data and revised the manuscript for important intellectual content. RP and KBF designed the study. KBF conceived of the study idea, supervised the study, and is the guarantor.

Corresponding author

Correspondence to Kristian B. Filion.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical standard

This study used published, aggregate data and did not involve human participants or animals. Consequently, research ethics board review was not required.

Informed consent

Not applicable

Additional information

Managed by Massimo Porta.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 8421 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Puckrin, R., Saltiel, MP., Reynier, P. et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 55, 503–514 (2018). https://doi.org/10.1007/s00592-018-1116-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-018-1116-0

Keywords

  • Sodium–glucose co-transporter 2 (SGLT-2) inhibitors
  • Type 2 diabetes mellitus
  • Infections
  • Adverse events
  • Systematic review and meta-analysis